Jikeqin (semaglutide SC once-weekly biosimilar) / Huadong Medicine - LARVOL DELTA

Efficacy and safety of HDM1702 vs. semaglutide (Wegovy®) in patients with obesity: a randomised, open-label, bioequivalence Phase 3 trial (EASD 2026) - P3 | "In patients with obesity, HDM1702 was equivalent to reference semaglutide (Wegovy®) in reduction of body weight at 44 weeks. HDM1702 was generally well tolerated in this population. The results of this study support the use of HDM1702 for weight management."

Clinical • P3 data • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

China’s Jiuyuan Genetic seeks approval for Wegovy biosimilar (WKZO) - "Jiuyuan said results of a Phase III trial ​in subjects with obesity showed Jikeqin was 'clinically equivalent' to a reference drug in terms of ⁠its safety profile, and in ⁠the percent change in patient body ​weight from baseline after 44 weeks after treatment."

China filing • Obesity